Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  nilotinib
Find trials that include:  Any drugs shown
Results 1-11 of 11 for your search:
Start Over
Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0697, NCI-2013-00551, NCT01751425
Nilotinib and Binimetinib in Treating Patients with Refractory or Advanced Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0128, NCI-2015-00044, CAMN107AUS41T, NCT02225574
Nilotinib in Treating Patients with Recurrent Glioblastoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 091728, NCI-2010-01839, NCI-2012-02871, NCT01140568
Targeted Therapy in Treating Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 to 69
Trial IDs: IRB00007195, NCI-2012-01084, CA180-392, NCT01620216
Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1284, NCI-2013-00469, 12-006178, NCT01806571
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and under
Trial IDs: CAMN107A2203, NCI-2014-01948, NCT01844765
Dasatinib or Nilotinib Followed by Imatinib Mesylate in Treating Patients with Newly Diagnosed, Previously Untreated, Chronic Phase Chronic Myeloid Leukemia
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 17 and over
Trial IDs: Winship3143-16, NCI-2016-00162, IRB00087045, NCT02709083
Nilotinib and External Beam Radiation Therapy in Treating Patients with High-Risk Chordoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-072, NCI-2011-03064, CAMN107YUS32T, NCT01407198
Ruxolitinib Phosphate and Nilotinib in Treating Patients with Chronic Myelogenous Leukemia
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC-17114, NCI-2013-00558, 12.09.0004, NCT01702064
Nilotinib and Cetuximab in Treating Patients With Solid Tumors That Can Be Treated With Cetuximab
Status: Not yet active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0039, NCI-2013-01168, NCT01871311
Nilotinib and Paclitaxel in Treating Patients with Refractory Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-C-0086, NCI-2014-00688, 9659, NCT02379416
Start Over